Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TCN-202
- Development stage
- Phase 1
- Lead developer
- Theraclone Sciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
TCN-202 is a recombinant, fully human monoclonal antibody developed for the treatment and prevention of cytomegalovirus (CMV) infections. It was discovered using Theraclone Sciences’ I-STAR platform, which identifies natural human antibodies with broad biologic activity. TCN-202 targets a universal protein within CMV variants, aiming to provide broad protection against the virus and reduce the risk of drug resistance due to viral mutations. The drug has been investigated particularly for use in immunocompromised individuals and congenital CMV infection, where complications can be severe or life-threatening. It received orphan drug designation for congenital CMV infection but development has since been discontinued[4][5][6][7][8][10].
- Other names
- human anti-cytomegalovirus monoclonal antibody
02
Targets
gB (Human cytomegalovirus glycoprotein B)IE1 (HCMV immediate-early protein 1)
Beyond the preview
Go deeper on TCN-202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TCN-202.